Large-Capacity Tabletop Freezer Expands Line
of Controlled-Rate Freezers for Cell and Gene Therapies; Now
Available for Order
BOTHELL,
Wash., June 6, 2023 /PRNewswire/ -- BioLife
Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or
the "Company"), a leading developer and supplier of class-defining
bioproduction products and services for the cell and gene therapy
(CGT) and broader biopharma markets, today announced the launch of
a new, large-capacity controlled-rate freezer (CRF) to expand its
CRF product line, which now stands at three different form factors.
Branded as the IntelliRate i67C, this tabletop freezer fulfills a
crucial customer need for higher volume production of cell
therapies.
Todd Berard, BioLife's Chief
Marketing Officer, commented, "With a capacity that's 40% larger
than other tabletop CRFs, IntelliRate i67C is perfectly sized to
efficiently scale precision rate freezing as a customer's capacity
needs grow. We designed the IntelliRate i67C to increase
single-batch, LN2 CRF capacity from mid- and late-stage clinical
research to initial commercial manufacturing
volumes. Fewer runs simplify the programming, setup, LN2
monitoring and power requirements, while the small footprint
preserves valuable lab space."
The IntelliRate i67C features 67-liter (2.35 cu. ft.) volume
inside the chamber, allowing for run capacities of 2,166 2mL vials,
26 (1 liter bag) to 104 (50mL bag) cassettes, or 272 canes. It
boasts the largest touchscreen controller in its class to execute a
wide range of preset and variable programming capabilities
including the setup of repeatable, 21 CFR Part 11-compliant freeze
profiles. The IntelliRate CRF also offers a range of options for
enhanced multi-probe monitoring, racking and sample
management.
Berard continued, "BioLife already has the largest selection of
controlled-rate freezer sizes and features. This new product
expands our cryogenic freezer platform with a larger capacity CRF
and allows us to support autologous and allogeneic CGT customers
from preclinical research though to commercial-scale
manufacturing. We're delighted to offer another critical cold
chain management tool to protect high-value biologic materials that
require precise control of the critical freezing process before
subsequent frozen storage."
The IntelliRate i67C is now available to order. To learn more
about the IntelliRate i67C and BioLife's complete line of freezers,
please visit us here or contact our sales or customer care team at
sales@custombiogenics.com.
About BioLife Solutions
BioLife Solutions is a leading
supplier of class-defining bioproduction tools and services for the
cell and gene therapy and broader biopharma markets. Our tools
portfolio includes our
proprietary CryoStor® and
HypoThermosol® biopreservation media for shipping
and storage, the ThawSTAR® family of automated,
water-free thawing products, evo® cold chain
management system, high capacity cryogenic controlled-rate
freezers, Stirling Ultracold mechanical
freezers, SciSafe biologic storage services, and Sexton
Biotechnologies cell processing tools. For more information,
please visit www.biolifesolutions.com or follow BioLife on
Twitter.
Cautions Regarding Forward Looking
Statements
Except for historical information contained
herein, this press release contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995. These forward-looking statements include, but are not
limited to, statements concerning the expected performance of the
Company's high capacity controlled-rate freezers, the demand for
and impact of the high capacity controlled-rate freezers for the
Company's customers, the average sale price and gross margin of the
high capacity controlled-rate freezers, and the impact on gross
margin of the high capacity controlled-rate freezers on the
Company's freezer line of products generally. All statements other
than statements of historical fact are statements that could be
deemed forward-looking statements. These statements are based on
management's current expectations and beliefs and are subject to a
number of risks, uncertainties and assumptions that could cause
actual results to differ materially from those described in the
forward-looking statements, including among other things,
uncertainty regarding unexpected costs associated with the
production or scaling up of production of the high capacity
controlled-rate freezers, market adoption of the high capacity
controlled-rate freezers specifically or the company's suite of
products generally, the ability of the company to implement its
business strategy, uncertainty regarding third-party market
projections, market volatility, competition, litigation, the impact
of the COVID-19 pandemic, and those other factors described in our
risk factors set forth in our filings with the Securities and
Exchange Commission from time to time, including our Annual Report
on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on
Form 8-K. We undertake no obligation to update the forward-looking
statements contained herein or to reflect events or circumstances
occurring after the date hereof, other than as may be required by
applicable law.
Media & Investor Relations
At the Company
Troy Wichterman
Chief Financial Officer
(425) 402-1400
twichterman@biolifesolutions.com
Investors
LHA Investor Relations
Jody Cain
(310) 691-7100
jcain@lhai.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/biolife-solutions-launches-the-intellirate-i67c-liquid-nitrogen-ln2-controlled-rate-freezer-301843061.html
SOURCE BioLife Solutions, Inc.